<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879526</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-003</org_study_id>
    <nct_id>NCT02879526</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma</brief_title>
  <official_title>Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II,Single-arm,Open-label, Muti-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate efficacy and safety of Chidamide Combined With
      Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With
      Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II,Single-arm,Open-label, Muti-center
      Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chidamide is a new histone deacetylase inhibitor and shows anti-tumor activity in
      Relapse/Refratory Peripheral T Cell Lymphoma.Cyclophosphamide、Prednisone、Thalidomide(CPT) is
      an oral combination regimen for lymphoma patients who can not stand the standard
      chemotherapy. The investigators therefore design this open-label,phase II, single-arm trial
      to investigate the efficacy of Chidamide Combined With CPT in treatment of fragile Patients
      With Relapse/Refratory Peripheral T Cell Lymphoma

      Primary Outcome Measures:

      • overall response rate

      Secondary Outcome Measures:

        -  duration of response

        -  progression free survival

        -  overall survival Enrollment:45 Study Start Date: August 2016 Primary Completion Date:
           March 2018
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>One-year</time_frame>
    <description>overall response rate after treated by C-CPT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>One-year</time_frame>
    <description>from the date of response to date of progression, relapse,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>One-year</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>One-year</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Relapse/Refratory Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-CPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-CPT</intervention_name>
    <description>Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd</description>
    <arm_group_label>C-CPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed Peripheral T Cell Lymphoma,exclude NK/T cell lymphoma

          2. Relapse or refractory to at least one prior therapy(chemotherapy or stem cell
             transplantation)

          3. can not

          4. age between 18 and 75, both gender

          5. ECOG PS 0-1

          6. Peripheral ANC &gt;1.5*109/L; platelet &gt;70*109/L; Hb≥ 90g/L

          7. Anticipated survival ≥ 3 months

          8. No chemotherapy 、radiotherapy and stem cell transplantation within 4 weeks before
             inclusion

          9. Sign in informed consent form, adherence to the study visit schedule and other
             protocol requirements

        Exclusion Criteria:

          1. Pregnant women or women in suckling period or with Potentia Generand but not willing
             to take contraceptives

          2. New York Heart Association class III or IV cardiac failure; oror history of following
             disease in past 6 months: acute coronary syndrome, acute heart failure, severe
             ventricular arrhythmia

          3. Poor hepatic function, defined as total bilirubin more than 1.5 fold of upper normal
             level, ALT, AST more than 2 fold of upper normal level or more than 5fold of upper
             normal level with hepatic involvement;Poor renal function, defined as serum creatinine
             more than 1.5 fold of upper normal level

          4. CNS or meningeal involvement

          5. intervention on myelosuppression within7 days before inclusion

          6. patients with active bleeding

          7. Major surgery within three weeks before inclusion

          8. Positive HIV, syphilis,HCV, or HBV virus load(HBV DNA)&gt; 1×105 copies/ml;

          9. Any psychological conditions which may disturb consent.

         10. In any conditions which investigator considered ineligible

         11. Known sensitivity or allergy to investigational Product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huayuan Zhu, M.D., Ph.D.</last_name>
    <phone>86 25 6813 6034</phone>
    <email>huayuan.zhu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HuaiAn First People's Hospital</name>
      <address>
        <city>HuaiAn</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Yu, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WuXi People's Hospital</name>
      <address>
        <city>WuXi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zhuang, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>YunFeng Shen, M.D., Ph.D</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sep 1;26(25):4124-30. doi: 10.1200/JCO.2008.16.4558. Epub 2008 Jul 14.</citation>
    <PMID>18626005</PMID>
  </reference>
  <reference>
    <citation>Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 May 15;112(10):2228-32. doi: 10.1002/cncr.23422.</citation>
    <PMID>18338745</PMID>
  </reference>
  <reference>
    <citation>Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9. doi: 10.1007/s00280-011-1766-x. Epub 2011 Nov 12.</citation>
    <PMID>22080169</PMID>
  </reference>
  <reference>
    <citation>Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. doi: 10.1093/annonc/mdv237. Epub 2015 Jun 23.</citation>
    <PMID>26105599</PMID>
  </reference>
  <reference>
    <citation>Gong K, Xie J, Yi H, Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012 May 1;443(3):735-46. doi: 10.1042/BJ20111685.</citation>
    <PMID>22339555</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2016</study_first_submitted>
  <study_first_submitted_qc>August 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 21, 2016</last_update_submitted>
  <last_update_submitted_qc>August 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Relapse/Refratory Peripheral T Cell Lymphoma</keyword>
  <keyword>Chidamide</keyword>
  <keyword>Cyclophosphamide、Prednisone、Thalidomide(CPT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

